Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acrivon Therapeutics, Inc. - Common Stock (NQ: ACRV )

7.520 +0.170 (+2.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acrivon Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Analyst Ratings for Acrivon Therapeutics
Via Benzinga
Recap: Acrivon Therapeutics Q3 Earnings
Via Benzinga
Analyst Expectations for Acrivon Therapeutics's Future
Via Benzinga
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics to Participate in Two Investor Conferences in September
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 18, 2023
Via Benzinga
Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
Dr. Levy brings more than 25 years of biopharma industry experience, including at Zentalis Pharmaceuticals, Turning Point Therapeutics and Gilead Sciences 
From Acrivon Therapeutics, Inc
Via GlobeNewswire
7 Up-and-Coming Stocks to Buy for the Next Decade
While less-established enterprises are best left for speculators, these up-and-coming stocks to buy also feature huge upside potential. 
Via InvestorPlace
Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors
Dr. Baum comes with more than 30 years of biopharma industry leadership experience, including at Mirati Therapeutics, Pfizer and Schering-Plough 
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.